HCW Biologics Inc. financial data

Symbol
HCWB on Nasdaq
Industry
Pharmaceutical Preparations
Location
2929 N Commerce Pkwy, Miramar, FL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 17 % -94.4%
Debt-to-equity -898 % -1919%
Return On Equity 840 %
Return On Assets -105 % -55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.9M shares +18.8%
Entity Public Float 12.8M USD -70.1%
Common Stock, Value, Issued 4.45K USD +23.6%
Weighted Average Number of Shares Outstanding, Basic 38.8M shares +7.97%
Weighted Average Number of Shares Outstanding, Diluted 38.8M shares +7.97%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 1.61M USD -29.5%
Research and Development Expense 6.39M USD -16.8%
General and Administrative Expense 6.84M USD +0.89%
Operating Income (Loss) -29.5M USD -14.6%
Nonoperating Income (Expense) 0 USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -30M USD -20.1%
Earnings Per Share, Basic -0.77 USD/shares -10%
Earnings Per Share, Diluted -0.77 USD/shares -10%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.67M USD +30%
Other Assets, Current 114K USD -50.8%
Assets, Current 5.7M USD -11%
Property, Plant and Equipment, Net 22.9M USD +12%
Operating Lease, Right-of-Use Asset 28.1K USD -85.3%
Other Assets, Noncurrent 28.5K USD -49.6%
Assets 30.2M USD +6.04%
Accounts Payable, Current 22.3M USD +262%
Liabilities, Current 29.6M USD +239%
Deferred Income Tax Liabilities, Net 40.9K USD -72.2%
Liabilities 37M USD +146%
Retained Earnings (Accumulated Deficit) -101M USD -42.6%
Stockholders' Equity Attributable to Parent -6.77M USD -150%
Liabilities and Equity 30.2M USD +6.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.6M USD +0.94%
Net Cash Provided by (Used in) Financing Activities 4.22M USD
Net Cash Provided by (Used in) Investing Activities -130K USD +56.8%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 44.5M shares +23.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 489K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.67M USD +30%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 26.2M USD +42.7%
Deferred Tax Assets, Gross 26.3M USD +41.8%
Payments to Acquire Property, Plant, and Equipment 130K USD -56.8%
Lessee, Operating Lease, Liability, to be Paid 343K USD
Property, Plant and Equipment, Gross 26.6M USD +13.2%
Operating Lease, Liability, Current 28.5K USD -84%
Lessee, Operating Lease, Liability, to be Paid, Year Two 49.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 294K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 28.8K USD -31.9%
Additional Paid in Capital 93.8M USD +11.7%
Depreciation, Depletion and Amortization 244K USD -18.5%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 28.7K USD -83.3%
Operating Leases, Future Minimum Payments Due 28.7K USD -85.7%
Interest Expense 631K USD +123%